[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@biotech_runner](/creator/twitter/biotech_runner)
"(1/3) $ROG continues to heavily invest in SERD despite the multiple setbacks in the field *4 current Phase X studies *Estimating $3B peak sales for giredestrant (2024 R&D Day) By comparison $OLMA at $550M is reasonable"  
[X Link](https://x.com/biotech_runner/status/1966480175388045697) [@biotech_runner](/creator/x/biotech_runner) 2025-09-12T12:33Z XXX followers, XXX engagements


"$OLMA +75% in the last month to $550M market cap from $PFE clinical supply deal and also analyst note (Oppenheimer) on pending $ROG persevERA / evERA readouts that are imminent X reasons why I believe there's more upside:"  
[X Link](https://x.com/biotech_runner/status/1966480173387452535) [@biotech_runner](/creator/x/biotech_runner) 2025-09-12T12:33Z XXX followers, XXX engagements


"$ROG Roche giredestrant hits PFS in 2L ER+/HER2- mBC in all comers and ESR1m Results from persevERA (1L ET-sensitive) pushed out to 2026 Some positive read-through to $OLMA"  
[X Link](https://x.com/biotech_runner/status/1970461998002708718) [@biotech_runner](/creator/x/biotech_runner) 2025-09-23T12:15Z XXX followers, XXX engagements